Production (Stage)
Galectin Therapeutics Inc.
GALT
$1.34
$0.021.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.42% | -1.05% | 2.58% | -9.44% | 3.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.15% | 29.99% | -1.09% | 25.41% | -6.71% |
| Operating Income | 18.15% | -29.99% | 1.09% | -25.41% | 6.71% |
| Income Before Tax | 16.17% | -19.71% | -7.59% | -35.74% | 0.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.17% | -19.71% | -7.59% | -35.74% | 0.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.17% | -19.71% | -7.59% | -35.74% | 0.33% |
| EBIT | 18.15% | -29.99% | 1.09% | -25.41% | 6.71% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 18.06% | -17.90% | 23.30% | -29.74% | 4.28% |
| Normalized Basic EPS | 17.86% | -18.02% | -3.11% | -29.92% | 4.29% |
| EPS Diluted | 18.06% | -17.90% | 23.30% | -29.87% | 4.28% |
| Normalized Diluted EPS | 17.86% | -18.02% | -3.11% | -29.92% | 4.29% |
| Average Basic Shares Outstanding | 1.98% | 1.42% | 4.31% | 4.45% | 4.20% |
| Average Diluted Shares Outstanding | 1.98% | 1.42% | 4.31% | 4.45% | 4.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |